Analyzing Cost of Revenue: Merck & Co., Inc. and Pharming Group N.V.

Merck vs. Pharming: A Decade of Cost Dynamics

__timestamp	Merck & Co., Inc.	Pharming Group N.V.
Wednesday, January 1, 2014	16768000000	4167274
Thursday, January 1, 2015	14934000000	5247851
Friday, January 1, 2016	13891000000	4925118
Sunday, January 1, 2017	12775000000	14930297
Monday, January 1, 2018	13509000000	25371768
Tuesday, January 1, 2019	14112000000	23921274
Wednesday, January 1, 2020	13618000000	25338236
Friday, January 1, 2021	13626000000	20182966
Saturday, January 1, 2022	17411000000	17562000
Sunday, January 1, 2023	16126000000	25212000

Unlocking the unknown

Analyzing Cost of Revenue: Merck & Co., Inc. vs. Pharming Group N.V.

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. Over the past decade, Merck & Co., Inc. and Pharming Group N.V. have showcased contrasting financial trajectories. From 2014 to 2023, Merck's cost of revenue fluctuated, peaking in 2022 with a 27% increase from its lowest point in 2017. In contrast, Pharming Group N.V. experienced a more consistent upward trend, with a remarkable 500% increase in cost of revenue from 2014 to 2023. This disparity highlights Merck's larger scale and operational complexity compared to Pharming's growth phase. As the pharmaceutical landscape continues to shift, these insights provide a window into the strategic decisions shaping the industry's giants and emerging players alike.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025